Symbols / FATE $1.37 +1.48% Fate Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
FATE Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Fundamentals
Scroll to Statements
Market Cap 159.28M Enterprise Value 33.48M Income -136.32M Sales 6.65M Book/sh 1.80 Cash/sh 1.75
Dividend Yield — Payout 0.00% Employees 161 IPO — P/E — Forward P/E -1.31
PEG — P/S 23.97 P/B 0.76 P/C — EV/EBITDA -0.25 EV/Sales 5.04
Quick Ratio 5.69 Current Ratio 5.79 Debt/Eq 37.58 LT Debt/Eq — EPS (ttm) -1.15 EPS next Y -1.05
EPS Growth — Revenue Growth -26.40% Earnings 2026-05-12 ROA -24.12% ROE -51.84% ROIC —
Gross Margin 0.00% Oper. Margin -24.56% Profit Margin 0.00% Shs Outstand 116.26M Shs Float 101.62M Short Float 9.66%
Short Ratio 6.71 Short Interest — 52W High 1.94 52W Low 0.91 Beta 2.24 Avg Volume 1.52M
Volume 700.87K Target Price $4.94 Recom None Prev Close $1.35 Price $1.37 Change 1.48%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.94
Mean price target
2. Current target
$1.37
Latest analyst target
3. DCF / Fair value
$-7.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.37
Low
$2.00
High
$8.00
Mean
$4.94

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-10-31 up HC Wainwright & Co. Neutral → Buy $5
2025-10-27 up Wedbush Neutral → Outperform $7
2025-10-27 reit Needham Hold → Hold —
2025-08-13 main Wells Fargo Equal-Weight → Equal-Weight $3
2025-06-12 reit Needham Hold → Hold —
2025-05-14 main Barclays Overweight → Overweight $2
2025-05-14 main Baird Neutral → Neutral $4
2025-05-14 reit Needham Hold → Hold —
2025-03-06 main Stifel Hold → Hold $3
2025-03-06 reit Wedbush Neutral → Neutral $5
2025-03-06 main Wells Fargo Equal-Weight → Equal-Weight $4
2025-03-06 reit Needham Hold → Hold —
2024-11-19 reit Needham — → Hold —
2024-11-13 reit Needham — → Hold —
2024-08-22 reit HC Wainwright & Co. Neutral → Neutral $5
2024-08-14 reit Needham — → Hold —
2024-06-17 up Piper Sandler Neutral → Overweight $6
2024-05-16 main HC Wainwright & Co. Neutral → Neutral $5
2024-05-10 main Canaccord Genuity Buy → Buy $9
2024-05-10 main BMO Capital Market Perform → Market Perform $6
News
RSS: Latest FATE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-15 TAHL CINDY R Officer — 100,000 $0.00 $0
2026-01-15 VALAMEHR BAHRAM Chief Executive Officer — 335,000 $0.00 $0
2026-01-15 ADAWI KAMAL Chief Financial Officer — 25,000 $0.00 $0
2026-01-09 TAHL CINDY R Officer — 10,589 $1.06 $11,275
2026-01-09 VALAMEHR BAHRAM Chief Executive Officer — 5,190 $1.07 $5,557
2025-10-20 ADAWI KAMAL Chief Financial Officer — 75,000 $0.00 $0
2025-08-04 TAHL CINDY R Officer — 9,037 $1.06 $9,573
2025-08-04 VALAMEHR BAHRAM Chief Executive Officer — 14,466 $1.06 $15,396
2025-01-15 TAHL CINDY R Officer — 70,000 $0.00 $0
2025-01-15 BRESSI JEROME CHARLES Officer — 65,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
6.65
-51.24%
13.63
-78.55%
63.53
-34.03%
96.30
Operating Revenue
6.65
-51.24%
13.63
-78.55%
63.53
-34.03%
96.30
Operating Expense
154.35
-26.21%
209.17
-17.66%
254.04
-37.22%
404.69
Research And Development
107.83
-20.13%
135.00
-21.78%
172.60
-46.14%
320.45
Selling General And Administration
46.52
-37.28%
74.17
-8.94%
81.45
-3.31%
84.23
General And Administrative Expense
46.52
-37.28%
74.17
-8.94%
81.45
-3.31%
84.23
Other Gand A
46.52
-37.28%
74.17
-8.94%
81.45
-3.31%
84.23
Total Expenses
154.35
-26.21%
209.17
-17.66%
254.04
-37.22%
404.69
Operating Income
-147.70
+24.46%
-195.54
-2.64%
-190.51
+38.22%
-308.39
Total Operating Income As Reported
-147.70
+29.76%
-210.28
-10.37%
-190.51
+38.22%
-308.39
EBITDA
-134.80
+23.66%
-176.58
-2.52%
-172.23
+41.54%
-294.63
Normalized EBITDA
-135.05
+16.98%
-162.66
+6.92%
-174.74
+44.51%
-314.94
Reconciled Depreciation
12.90
-31.96%
18.96
+3.72%
18.28
+32.88%
13.76
EBIT
-147.70
+24.46%
-195.54
-2.64%
-190.51
+38.22%
-308.39
Total Unusual Items
0.24
+101.75%
-13.92
-653.40%
2.52
-87.62%
20.31
Total Unusual Items Excluding Goodwill
0.24
+101.75%
-13.92
-653.40%
2.52
-87.62%
20.31
Special Income Charges
0.00
+100.00%
-14.74
0.00
—
Impairment Of Capital Assets
0.00
-100.00%
14.74
0.00
—
Net Income
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Pretax Income
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Net Non Operating Interest Income Expense
11.05
-36.07%
17.29
+0.59%
17.19
+194.18%
5.84
Interest Expense Non Operating
—
—
—
—
Net Interest Income
11.05
-36.07%
17.29
+0.59%
17.19
+194.18%
5.84
Interest Expense
—
—
—
—
Interest Income Non Operating
11.05
-36.07%
17.29
+0.59%
17.19
+194.18%
5.84
Interest Income
11.05
-36.07%
17.29
+0.59%
17.19
+194.18%
5.84
Other Income Expense
0.34
+104.21%
-8.01
-164.62%
12.40
-40.46%
20.82
Other Non Operating Income Expenses
0.09
-98.43%
5.91
-40.22%
9.88
+1815.12%
0.52
Gain On Sale Of Security
0.24
-70.21%
0.82
-67.44%
2.52
-87.62%
20.31
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Net Income From Continuing Operation Net Minority Interest
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Net Income From Continuing And Discontinued Operation
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Net Income Continuous Operations
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Normalized Income
-136.56
+20.76%
-172.34
-5.45%
-163.44
+45.88%
-302.03
Net Income Common Stockholders
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Diluted EPS
-1.15
+29.88%
-1.64
+0.00%
-1.64
+43.64%
-2.91
Basic EPS
-1.15
+29.88%
-1.64
+0.00%
-1.64
+43.64%
-2.91
Basic Average Shares
118.79
+4.49%
113.69
+15.52%
98.41
+1.64%
96.83
Diluted Average Shares
118.79
+4.49%
113.69
+15.52%
98.41
+1.64%
96.83
Diluted NI Availto Com Stockholders
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
318.94
-27.63%
440.69
-12.94%
506.22
-28.25%
705.56
Current Assets
208.70
-28.50%
291.91
-11.95%
331.54
-33.97%
502.07
Cash Cash Equivalents And Short Term Investments
203.66
-27.02%
279.07
-11.46%
315.18
-27.75%
436.23
Cash And Cash Equivalents
46.63
+29.32%
36.06
-13.89%
41.87
-31.73%
61.33
Other Short Term Investments
157.03
-35.38%
243.01
-11.08%
273.31
-27.10%
374.89
Receivables
0.92
-74.12%
3.54
+93.81%
1.83
-95.25%
38.48
Accounts Receivable
0.92
-74.12%
3.54
+93.81%
1.83
-95.25%
38.48
Prepaid Assets
—
—
—
—
Other Current Assets
4.13
-55.59%
9.30
-36.02%
14.54
-46.87%
27.37
Total Non Current Assets
110.23
-25.91%
148.78
-14.82%
174.68
-14.16%
203.49
Net PPE
98.53
-11.14%
110.89
-30.04%
158.51
-9.98%
176.09
Gross PPE
134.76
-7.72%
146.03
-29.16%
206.14
-0.16%
206.47
Accumulated Depreciation
-36.22
-3.09%
-35.14
+26.23%
-47.63
-56.75%
-30.38
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
103.96
-1.91%
105.99
-12.19%
120.71
-1.74%
122.85
Machinery Furniture Equipment
3.08
-25.58%
4.14
-37.00%
6.57
+4.83%
6.27
Construction In Progress
—
—
—
—
Other Properties
27.71
-22.80%
35.90
-54.48%
78.85
+1.94%
77.35
Leases
—
59.48
+0.76%
59.04
+3.97%
56.78
Investments And Advances
1.47
-94.68%
27.66
+2722.14%
0.98
-80.17%
4.94
Non Current Accounts Receivable
—
—
—
7.20
Other Non Current Assets
10.23
-0.09%
10.24
-32.60%
15.19
-0.48%
15.26
Total Liabilities Net Minority Interest
111.75
-8.38%
121.97
-11.49%
137.80
-37.82%
221.62
Current Liabilities
36.07
-6.36%
38.52
-1.46%
39.09
-65.72%
114.05
Payables And Accrued Expenses
22.68
-26.16%
30.71
-4.72%
32.23
-48.18%
62.20
Payables
2.66
-71.64%
9.37
+98.45%
4.72
-42.90%
8.27
Accounts Payable
2.66
-71.64%
9.37
+98.45%
4.72
-42.90%
8.27
Current Accrued Expenses
20.02
-6.20%
21.35
-22.41%
27.51
-48.98%
53.93
Current Debt And Capital Lease Obligation
4.56
-38.48%
7.42
+20.08%
6.18
+9.74%
5.63
Current Capital Lease Obligation
4.56
-38.48%
7.42
+20.08%
6.18
+9.74%
5.63
Current Deferred Liabilities
0.38
-3.05%
0.39
-42.63%
0.69
-98.38%
42.23
Current Deferred Revenue
0.38
-3.05%
0.39
-42.63%
0.69
-98.38%
42.23
Other Current Liabilities
8.45
—
—
4.00
Total Non Current Liabilities Net Minority Interest
75.68
-9.30%
83.45
-15.46%
98.71
-8.24%
107.57
Long Term Debt And Capital Lease Obligation
73.29
-5.86%
77.85
-20.04%
97.36
-6.12%
103.71
Long Term Capital Lease Obligation
73.29
-5.86%
77.85
-20.04%
97.36
-6.12%
103.71
Non Current Deferred Liabilities
—
—
—
0.00
Non Current Deferred Revenue
—
—
—
0.00
Other Non Current Liabilities
2.11
-58.34%
5.07
—
—
Stockholders Equity
207.18
-35.00%
318.73
-13.49%
368.42
-23.87%
483.94
Common Stock Equity
207.18
-35.00%
318.72
-13.49%
368.41
-23.87%
483.94
Capital Stock
0.12
+0.85%
0.12
+14.71%
0.10
+2.00%
0.10
Common Stock
0.12
+0.88%
0.11
+15.15%
0.10
+2.06%
0.10
Preferred Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
115.36
+1.26%
113.93
+15.51%
98.63
+1.37%
97.29
Ordinary Shares Number
115.36
+1.26%
113.93
+15.51%
98.63
+1.37%
97.29
Additional Paid In Capital
1,741.26
+1.45%
1,716.34
+8.63%
1,580.03
+2.83%
1,536.50
Retained Earnings
-1,534.31
-9.75%
-1,397.99
-15.37%
-1,211.73
-15.31%
-1,050.80
Gains Losses Not Affecting Retained Earnings
0.12
-56.72%
0.27
+1686.67%
0.01
+100.81%
-1.85
Other Equity Adjustments
0.12
-56.72%
0.27
+1686.67%
0.01
+100.81%
-1.85
Total Equity Gross Minority Interest
207.18
-35.00%
318.73
-13.49%
368.42
-23.87%
483.94
Total Capitalization
207.18
-35.00%
318.73
-13.49%
368.42
-23.87%
483.94
Working Capital
172.63
-31.87%
253.39
-13.36%
292.45
-24.63%
388.02
Invested Capital
207.18
-35.00%
318.72
-13.49%
368.41
-23.87%
483.94
Total Debt
77.85
-8.70%
85.27
-17.65%
103.54
-5.31%
109.34
Capital Lease Obligations
77.85
-8.70%
85.27
-17.65%
103.54
-5.31%
109.34
Net Tangible Assets
207.18
-35.00%
318.73
-13.49%
368.42
-23.87%
483.94
Tangible Book Value
207.18
-35.00%
318.72
-13.49%
368.41
-23.87%
483.94
Available For Sale Securities
1.47
-94.68%
27.66
+2722.14%
0.98
-80.17%
4.94
Derivative Product Liabilities
0.28
-46.30%
0.53
-60.85%
1.35
-65.14%
3.86
Investmentin Financial Assets
1.47
-94.68%
27.66
+2722.14%
0.98
-80.17%
4.94
Preferred Stock Equity
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-106.08
+13.66%
-122.87
+7.10%
-132.26
+46.71%
-248.21
Cash Flow From Continuing Operating Activities
-106.08
+13.66%
-122.87
+7.10%
-132.26
+46.71%
-248.21
Net Income From Continuing Operations
-136.31
+26.82%
-186.26
-15.74%
-160.93
+42.88%
-281.72
Depreciation Amortization Depletion
12.90
-31.96%
18.96
+3.72%
18.28
+32.88%
13.76
Depreciation And Amortization
12.90
-31.96%
18.96
+3.72%
18.28
+32.88%
13.76
Other Non Cash Items
-0.26
+85.04%
-1.71
+95.81%
-40.86
-70.16%
-24.01
Stock Based Compensation
24.92
-39.94%
41.50
-4.52%
43.46
-44.80%
78.73
Asset Impairment Charge
0.00
-100.00%
14.74
0.00
—
Operating Gains Losses
0.01
-99.04%
0.94
—
—
Gain Loss On Sale Of PPE
0.01
-99.04%
0.94
0.00
—
Change In Working Capital
-3.74
-91.06%
-1.96
-110.21%
19.18
+155.26%
-34.71
Change In Receivables
2.62
+335.76%
-1.11
-103.04%
36.65
+222.98%
-29.80
Changes In Account Receivables
2.62
+335.76%
-1.11
-103.04%
36.65
+222.98%
-29.80
Change In Prepaid Assets
5.18
-1.11%
5.24
-59.33%
12.88
+170.25%
-18.33
Change In Payables And Accrued Expense
-9.03
-443.47%
-1.66
+94.26%
-28.94
-303.06%
14.25
Change In Other Working Capital
-2.52
+43.07%
-4.42
-213.99%
-1.41
-70.05%
-0.83
Investing Cash Flow
111.17
+809.85%
12.22
-89.16%
112.67
-32.44%
166.75
Cash Flow From Continuing Investing Activities
111.17
+809.85%
12.22
-89.16%
112.67
-32.44%
166.75
Net PPE Purchase And Sale
-5.59
-665.89%
-0.73
+88.14%
-6.15
+82.70%
-35.57
Purchase Of PPE
-5.95
-715.48%
-0.73
+88.14%
-6.15
+82.70%
-35.57
Sale Of PPE
0.36
0.00
—
—
Capital Expenditure
-5.95
-715.48%
-0.73
+88.14%
-6.15
+82.70%
-35.57
Net Investment Purchase And Sale
116.76
+801.74%
12.95
-89.10%
118.82
-41.27%
202.32
Purchase Of Investment
-195.14
+38.59%
-317.75
+11.44%
-358.81
+11.36%
-404.80
Sale Of Investment
311.90
-5.68%
330.70
-30.76%
477.63
-21.33%
607.11
Financing Cash Flow
5.49
-94.50%
99.89
+117420.00%
0.09
-99.08%
9.21
Cash Flow From Continuing Financing Activities
5.49
-94.50%
99.89
+117420.00%
0.09
-99.08%
9.21
Net Issuance Payments Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
-100.00%
74.53
0.00
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
20.29
+23771.76%
0.09
-99.08%
9.21
Net Other Financing Charges
5.49
+8.28%
5.07
—
—
Changes In Cash
10.57
+198.22%
-10.76
+44.84%
-19.51
+72.99%
-72.25
Beginning Cash Position
46.28
-18.87%
57.05
-25.49%
76.56
-48.55%
148.81
End Cash Position
56.85
+22.84%
46.28
-18.87%
57.05
-25.49%
76.56
Free Cash Flow
-112.04
+9.36%
-123.60
+10.70%
-138.42
+51.22%
-283.77
Interest Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-3.61
+60.29%
-9.08
+20.34%
-11.40
-4352.34%
-0.26
Common Stock Issuance
0.00
-100.00%
74.53
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
74.53
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category